Skip to main content
Applied and Environmental Microbiology logoLink to Applied and Environmental Microbiology
. 2010 Dec 30;77(5):1885–1887. doi: 10.1128/AEM.01176-10

Plasmid-Mediated Quinolone Resistance in Pseudomonas putida Isolates from Imported Shrimp

Quynh T Tran 1,*, Mohamed S Nawaz 1, Joanna Deck 1, Kiet T Nguyen 2, Carl E Cerniglia 1
PMCID: PMC3067295  PMID: 21193671

Abstract

Fourteen quinolone-resistant Pseudomonas putida isolates were recovered from imported frozen shrimp sold in the United States. Two isolates harbored plasmids with qnrA and qnrB genes. PCR and DNA sequencing of quinolone resistance-determining regions identified novel substitutions in GyrA (His139→Glu and Thr128→Ala) and GyrB (Thr442→Asn, Gly470→Ala, and Ile487→Pro) and previously reported substitutions in GyrB (Asp489→Glu) and ParC (Thr105→Pro).


The administration of quinolones, including nalidixic acid, oxolinic acid, enrofloxacin, norfloxacin, and ciprofloxacin, is a common practice in the shrimp-farming industry of developing countries, raising concern over the generation of multiresistant pathogenic bacteria (7, 11, 17). Pseudomonas putida is a fast-growing organism that is found in most temperate soil and water habitats and causes opportunistic infections in humans (2, 16, 19, 21). This study describes the isolation, characterization, and detection of quinolone resistance mechanisms among P. putida isolates from imported shrimp.

Fourteen isolates of P. putida were isolated from a total of 10 samples of farm-raised, frozen, whole raw shrimp (Penaeus spp.) imported from India and purchased in retail stores (Little Rock, AR). One gram of shrimp was taken from three individual bags and homogenized in a stomacher with 10 ml of LB broth supplemented with 10 μg/ml of nalidixic acid. The homogenate was enriched overnight at 37°C, and 100 to 200 μl was subcultured onto TSAII plates (Becton Dickinson, Franklin Lakes, NJ). Isolates were confirmed as P. putida using VITEK 2 Gram-negative identification cards (bioMérieux, Durham, NC).

Pulsed-field gel electrophoresis (PFGE) analysis was performed using the Centers for Disease Control and Prevention procedure for Salmonella (http://www.cdc.gov/pulsenet/protocols.htm) to assess the genetic relatedness among the P. putida isolates recovered from the shrimp. Upon examination of PFGE patterns from SpeI restriction digests of DNA from the 14 P. putida strains, 10 clusters, each containing 14 to 20 restriction fragments, were apparent (Fig. 1).

FIG. 1.

FIG. 1.

Dendrogram generated by unweighted-pair group method using average linkage (UPGMA) analysis, using Bionumerics software, showing the results of cluster analysis of PFGE profiles of Pseudomonas putida isolates from imported shrimp digested with SpeI. The clusters are marked I through X.

The antimicrobial MICs for P. putida isolates were determined using the Sensititre automated antimicrobial susceptibility system according to the manufacturer's instructions (25) and interpreted based on the CLSI criteria (5). When the β-lactam antimicrobial MICs were determined, all isolates were found resistant to cefoxitin, amoxicillin-clavulanic acid, ceftiofur, and ampicillin, and 8 of the 14 were resistant to ceftriaxone. When the aminoglycoside MICs were determined, the most isolates were found to be resistant to kanamycin (10/14 isolates), followed by streptomycin (9/14), amikacin (9/14), and gentamicin (1/14). When the remaining antimicrobial MICs were determined, all isolates were found resistant to sulfisoxazole and 12 of the 14 were resistant to chloramphenicol, tetracycline, and trimethroprim-sulfamethoxazole. All isolates were resistant to nalidixic acid (≥32 μg/ml). Isolate PP3 exhibited intermediate resistance to ciprofloxacin (2 μg/ml). All other isolates possessed various susceptibilities to ciprofloxacin, ranging from 0.25 to 1 μg/ml. MICs determined for nalidixic acid and ciprofloxacin corresponding to the P. putida isolates grouped by PFGE patterns are displayed in Table 1.

TABLE 1.

Characteristics of QRDR substitutions and quinolone MICS for Pseudomonas putida isolates from imported shrimp

PFGE pattern Isolate MIC (μg/ml) of:
Amino acid change(s)
Nala Cipb GyrA GyrB ParC
I PP1 ≥32 1 His139→Glu
PP17 ≥32 1 His139→Glu
PP18 ≥32 1 His139→Glu
PP20 ≥32 1 His139→Glu
II PP19 ≥32 1 His139→Glu
III PP10 ≥32 1 Thr128→Ala, His139→Glu
IV PP16 ≥32 0.25 Thr442→Asn, Gly470→Ala, Ile487→Pro
V PP21 ≥32 0.25 Thr105→Pro
VI PP24 ≥32 0.25 Thr105→Pro
PP25 ≥32 0.50 His139→Glu Thr105→Pro
VII PP3 ≥32 2 His139→Glu Asp489→Glu Thr105→Pro
VIII PP13 ≥32 1 His139→Glu
IX PP6 ≥32 1 His139→Glu
X PP15 ≥32 1 His139→Glu
a

The resistance breakpoint for Nal (nalidixic acid) according to CLSI standards (5) is ≥32 μg/ml.

b

The resistance breakpoint for Cip (ciprofloxacin) according to CLSI standards (5) is ≥4 μg/ml.

Limited studies with clinical P. putida isolates report that fluoroquinolone resistance involves point substitutions in DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC) (12). The amplification of quinolone resistance-determining regions (QRDRs) of gyrA (∼400 bp), gyrB (∼370 bp), and parC (∼180 bp) was carried out with previously published primers and amplification conditions (1). DNA sequences were analyzed using the Pseudomonas Genome Database BLAST (28).

Among the QRDRs, a majority (11/14) of the isolates contained a single replacement in GyrA (His-139→Glu). Isolate PP10 possessed an additional substitution in GyrA (Thr-128→Ala). For GyrB, a single substitution in PP3 (Asp-489→Glu) and three substitutions in PP16 (Thr-442→Asn, Gly-470→Ala, and Ile-487→Pro) were identified. Four of the isolates (PP21, PP24, PP25, and PP3) showed the replacement of Thr-105 by Pro in ParC. The substitutions detected in parC (Thr-105→Pro) and gyrB (Asp-489→Glu) agreed with findings from a previous study (12). Our findings of amino acid changes in GyrA and GyrB differed somewhat from those of the previous study, which reported substitutions such as Thr-83→Ile and Ser-136→Ala in GyrA and Glu-469→Asp in GyrB as possible substitutions contributing to high levels of fluoroquinolone resistance in human clinical isolates (12). Moreover, our findings differed from GyrA substitutions in clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Pseudomas aeruginosa, which have been shown to comprise Ser-83→Ile, Ser-83→Leu, and Thr-83→Ile, respectively (4, 6, 27). A possible explanation for these discrepancies may be related to the sources of the isolates examined.

Interestingly, among the isolates in this study, PP3 exhibited a higher level of resistance to ciprofloxacin and possessed substitutions in gyrA, gyrB, and parC QRDRs, suggesting that, as found in other Enterobacteriaceae, high-level fluoroquinolone resistance may be associated with an increased number of substitutions present in the QRDRs (4, 9).

In 1998, the first plasmid-mediated quinolone resistance gene (qnr) was discovered in a Klebsiella pneumoniae clinical isolate (18). The qnr plasmid mediates low-level quinolone resistance and facilitates selection of higher-level resistance mutations (18). The original qnr gene is now designated qnrA because two other plasmid-mediated quinolone resistance genes, qnrB (14) and qnrS (8), possess mechanisms of action similar to that of qnrA in reducing fluoroquinolone activity. Plasmid extraction was performed using a QIAprep spin miniprep kit (Qiagen Inc., Valencia, CA) on the 14 P. putida isolates, but plasmids were recovered from 2, PP16 and PP19. PCR assays using previously published primers (29) detected qnrA and qnrB but not qnrS in both plasmids. Subsequently, PCR products for qnrA and qnrB were confirmed by restriction enzyme digestion and nucleotide sequencing.

Shewanella algae, a Gram-negative bacterium of marine and fresh water, was recently identified as a possible natural source of the plasmid-mediated quinolone resistance determinant QnrA (22). Since quinolones are widely administered in the aquaculture of less developed countries, including the shrimp-farming industry (11), it is possible at any concentration of quinolones, including low concentrations, to select for waterborne S. algae strains and promote the horizontal transfer of qnr genes to other bacteria, including P. putida found in water habitats. The generation of resistant pathogens in aquaculture environments is well documented (10, 15, 26, 31), and evidence of transfer of resistance-encoding plasmids between bacteria found in aquaculture environments and humans has been shown (23). Therefore, it can be speculated that the aquatic environment may play a possible role as a reservoir for antibiotic resistance genes.

The transferability of plasmid-mediated quinolone resistance in P. putida strains harboring qnrA and qnrB genes was studied. Plasmids were transferred from P. putida to Escherichia coli J53 Azir by conjugation using sodium azide (100 μg/ml) for counterselection (13). Ceftazidime (10 μg/ml) was used in mating experiments instead of quinolones to avoid selection of quinolone resistance chromosomal mutations and because of the strong association between qnr genes and plasmids carrying cephalosporinase genes (3, 18, 20, 24). To determine if quinolone resistance was transferred, the MICs for the donor, recipient, and transconjugant were measured and evaluated with 30-μg nalidixic acid disks.

The MIC of nalidixic acid for transconjugants demonstrated an 8-fold increase, from 4 μg/ml to 32 μg/ml, over the MIC for the recipient E. coli strain J53. The MIC of ciprofloxacin for transconjugants demonstrated approximately a 4-fold increase, from 0.06 μg/ml to 0.25 μg/ml, over that for the recipient E. coli strain J53. The plasmid carrying qnrA and qnrB genes provided resistance to ciprofloxacin and nalidixic acid, a finding which agreed with earlier reports (14, 18). The inhibition zones for recipient and donor strains were 18 mm and 8 mm, interpreted as susceptible and resistant, respectively. No zone of inhibition was present for the transconjugant, indicating that the recipient E. coli J53 had acquired quinolone resistance. Transconjugants also displayed decreased susceptibility to cefoxitin, chloramphenicol, amoxicillin-clavulanic acid, and ampicillin, suggesting that the plasmid may carry additional antibiotic resistance elements, as shown in previous studies (18, 29, 30).

In summary, the findings of mutations in the bacterial enzymes DNA gyrase and topoisomerase IV and plasmid-borne qnr genes among P. putida isolates from shrimp in this study support reports that the use of antimicrobial agents in aquaculture might promote an increase in the frequency of antibiotic resistance genes in the microbiota of finfish, crustaceans, shellfish, and the environment.

Acknowledgments

We thank George A. Jacoby for providing the E. coli J53 Azir recipient strain used in the conjugation experiments. We thank Steven Foley and John B. Sutherland for critical review of the manuscript.

This work was supported by the National Center for Toxicological Research, U.S. Food and Drug Administration (FDA). Q.T.T. and K.T.N. were supported by the FDA Commissioner's Fellowship Program.

The views presented here do not necessarily reflect those of the FDA.

Footnotes

Published ahead of print on 30 December 2010.

REFERENCES

  • 1.Akasaka, T., M. Tanaka, A. Yamaguchi, and K. Sato. 2001. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45:2263-2268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bouallègue, O., et al. 2004. Outbreak of Pseudomonas putida bacteraemia in a neonatal intensive care unit. J. Hosp. Infect. 57:88-91. [DOI] [PubMed] [Google Scholar]
  • 3.Cattoir, V., L. Poirel, V. Rotimi, C. J. Soussy, and P. Nordmann. 2007. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J. Antimicrob. Chemother. 60:394-397. [DOI] [PubMed] [Google Scholar]
  • 4.Chen, F. J., T. L. Lauderdale, M. Ho, and H. J. Lo. 2003. The roles of mutations in gyrA, parC, and ompK35 in fluoroquinolone resistance in Klebsiella pneumoniae. Microb. Drug Resist. 9:265-271. [DOI] [PubMed] [Google Scholar]
  • 5.CLSI. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. M100-S20. Clinical Laboratory Standards Institute, Wayne, PA.
  • 6.Conrad, S., et al. 1996. gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. J. Antimicrob. Chemother. 38:443-455. [DOI] [PubMed] [Google Scholar]
  • 7.Gräslund, S., K. Holmstrom, and A. Wahlstrom. 2003. A field survey of chemicals and biological products used in shrimp farming. Mar. Pollut. Bull. 46:81-90. [DOI] [PubMed] [Google Scholar]
  • 8.Hata, M., et al. 2005. Cloning of a novel gene for quinolone resistance from a transferable plasmid in Shigella flexneri 2b. Antimicrob. Agents Chemother. 49:801-803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Heisig, P. 1996. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40:879-885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Heuer, O. E., et al. 2009. Human health consequences of use of antimicrobial agents in aquaculture. Clin. Infect. Dis. 49:1248-1253. [DOI] [PubMed] [Google Scholar]
  • 11.Holmstrom, K., et al. 2003. Antibiotic use in shrimp farming and implications for environmental impacts and human health. Int. J. Food Sci. Technol. 38:255-266. [Google Scholar]
  • 12.Horii, T., H. Muramatsu, and Y. Iinuma. 2005. Mechanisms of resistance to fluoroquinolones and carbapenems in Pseudomonas putida. J. Antimicrob. Chemother. 56:643-647. [DOI] [PubMed] [Google Scholar]
  • 13.Jacoby, G. A., and P. Han. 1996. Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J. Clin. Microbiol. 34:908-911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Jacoby, G. A., et al. 2006. qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob. Agents Chemother. 50:1178-1182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kümmerer, K. 2004. Resistance in the environment. J. Antimicrob. Chemother. 54:311-320. [DOI] [PubMed] [Google Scholar]
  • 16.Ladhani, S., and Z. A. Bhutta. 1998. Neonatal Pseudomonas putida infection presenting as staphylococcal scalded skin syndrome. Eur. J. Clin. Microbiol. Infect. Dis. 17:642-644. [DOI] [PubMed] [Google Scholar]
  • 17.Le, T. X., Y. Munekage, and S. Kato. 2005. Antibiotic resistance in bacteria from shrimp farming in mangrove areas. Sci. Total Environ. 349:95-105. [DOI] [PubMed] [Google Scholar]
  • 18.Martínez-Martínez, L., A. Pascual, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet 351:797-799. [DOI] [PubMed] [Google Scholar]
  • 19.Martino, R., et al. 1996. Bacteremia due to glucose non-fermenting gram-negative bacilli in patients with hematological neoplasias and solid tumors. Eur. J. Clin. Microbiol. Infect. Dis. 15:610-615. [DOI] [PubMed] [Google Scholar]
  • 20.Nordmann, P., and L. Poirel. 2005. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J. Antimicrob. Chemother. 56:463-469. [DOI] [PubMed] [Google Scholar]
  • 21.Perz, J. F., et al. 2005. Pseudomonas putida septicemia in a special care nursery due to contaminated flush solutions prepared in a hospital pharmacy. J. Clin. Microbiol. 43:5316-5318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Poirel, L., J. M. Rodriguez-Martinez, H. Mammeri, A. Liard, and P. Nordmann. 2005. Origin of plasmid-mediated quinolone resistance determinant QnrA. Antimicrob. Agents Chemother. 49:3523-3525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Rhodes, G., et al. 2000. Distribution of oxytetracycline resistance plasmids between aeromonads in hospital and aquaculture environments: implication of Tn1721 in dissemination of the tetracycline resistance determinant tetA. Appl. Environ. Microbiol. 66:3883-3890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Robicsek, A., J. Strahilevitz, D. F. Sahm, G. A. Jacoby, and D. C. Hooper. 2006. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob. Agents Chemother. 50:2872-2874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Rubin, J., R. D. Walker, K. Blickenstaff, S. Bodeis-Jones, and S. Zhao. 2008. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections. Vet. Microbiol. 131:164-172. [DOI] [PubMed] [Google Scholar]
  • 26.Sørum, H. 1999. Antibiotic resistance in aquaculture. Acta Vet. Scand. Suppl. 92:29-36. [PubMed] [Google Scholar]
  • 27.Takenouchi, T., E. Sakagawa, and M. Sugawara. 1999. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrob. Agents Chemother. 43:406-409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Winsor, G. L., et al. 2009. Pseudomonas Genome Database: facilitating user-friendly, comprehensive comparisons of microbial genomes. Nucleic Acids Res. 37:D483-D488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wu, J. J., W. C. Ko, H. M. Wu, and J. J. Yan. 2008. Prevalence of Qnr determinants among bloodstream isolates of Escherichia coli and Klebsiella pneumoniae in a Taiwanese hospital, 1999-2005. J. Antimicrob. Chemother. 61:1234-1239. [DOI] [PubMed] [Google Scholar]
  • 30.Yang, H., H. Chen, Q. Yang, M. Chen, and H. Wang. 2008. High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6′)-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. Antimicrob. Agents Chemother. 52:4268-4273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Young, H. K. 1993. Antimicrobial resistance spread in aquatic environments. J. Antimicrob. Chemother. 31:627-635. [DOI] [PubMed] [Google Scholar]

Articles from Applied and Environmental Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES